Medtronic PLC $MDT Stock: Quadrant Capital Group LLC Raises Holdings

Quadrant Capital Group LLC increased its holdings in Medtronic PLC (NYSE:MDT) by 109.0% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 11,063 shares of the medical technology company’s stock after purchasing an additional 5,770 shares during the quarter. Quadrant Capital Group LLC’s holdings in Medtronic were worth $1,029,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in MDT. Petredis Investment Advisors LLC boosted its position in Medtronic by 0.4% during the 3rd quarter. Petredis Investment Advisors LLC now owns 26,369 shares of the medical technology company’s stock worth $2,275,000 after acquiring an additional 114 shares during the period. Arlington Trust Co LLC grew its stake in shares of Medtronic by 11.6% in the second quarter. Arlington Trust Co LLC now owns 1,157 shares of the medical technology company’s stock worth $91,000 after purchasing an additional 120 shares in the last quarter. Bigelow Investment Advisors LLC increased its holdings in shares of Medtronic by 1.1% during the first quarter. Bigelow Investment Advisors LLC now owns 11,125 shares of the medical technology company’s stock valued at $964,000 after purchasing an additional 121 shares during the period. Bank & Trust Co increased its holdings in shares of Medtronic by 2.8% during the second quarter. Bank & Trust Co now owns 4,373 shares of the medical technology company’s stock valued at $342,000 after purchasing an additional 121 shares during the period. Finally, Grove Bank & Trust raised its stake in shares of Medtronic by 1.2% during the third quarter. Grove Bank & Trust now owns 10,564 shares of the medical technology company’s stock valued at $912,000 after purchasing an additional 124 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Stock Down 1.1%

MDT opened at $95.48 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. The company has a market capitalization of $122.13 billion, a PE ratio of 16.89, a P/E/G ratio of 2.26 and a beta of 0.55. The stock’s fifty day moving average is $91.43 and its 200-day moving average is $85.30. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. During the same quarter last year, the business posted $1.26 earnings per share. The company’s quarterly revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities analysts predict that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend was Friday, September 25th. Medtronic’s dividend payout ratio is presently 70.94%.

Analyst Ratings Changes

MDT has been the subject of several research analyst reports. Wall Street Zen raised shares of Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, October 3rd. Evercore set a $105.00 target price on shares of Medtronic in a research note on Monday, July 6th. TD Cowen restated a “buy” rating and set a $110.00 price target on shares of Medtronic in a research report on Wednesday, September 30th. Royal Bank Of Canada restated an “outperform” rating and set a $118.00 price target on shares of Medtronic in a research report on Wednesday, September 2nd. Finally, Wells Fargo & Company upped their price target on shares of Medtronic from $102.00 to $104.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 2nd. Eighteen equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and an average target price of $102.88.

Insider Buying and Selling at Medtronic

In other news, CEO Geoffrey Martha sold 50,000 shares of the firm’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the completion of the transaction, the chief executive officer owned 277,866 shares in the company, valued at approximately $26,397,270. This trade represents a 15.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Marinaro sold 10,420 shares of Medtronic stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the transaction, the executive vice president directly owned 105,916 shares in the company, valued at $10,167,936. This represents a 8.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 61,903 shares of company stock valued at $5,889,203. 0.27% of the stock is owned by insiders.

About Medtronic

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.